CEACAM5 and neoplasm: Conventional CEA-specific antibodies can bind with high affinity and selectivity to CEA-expressing (CEA+) tumours in vivo but they do not recognise CEA expressed on the luminal side of several normal epithelial tissues, thus limiting their potential toxicity (Mayer et al, 2000).